{"disease":{"id":"non-small-cell-carcinoma","name":"non small cell carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06996249","title":"Prospective Data Collection Initiative on Thoracic Malignancies","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Dutch Society of Physicians for Pulmonology and Tuberculosis","has_results":false},{"nct_id":"NCT02194738","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8300,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02728596","title":"S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)","phase":"NA","overall_status":"COMPLETED","enrollment_count":3665,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT04825873","title":"A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China","phase":"","overall_status":"COMPLETED","enrollment_count":3102,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03782207","title":"A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2756,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03605602","title":"A Real World Study Based on NGS (TRUMPRWS)","phase":"","overall_status":"UNKNOWN","enrollment_count":2700,"lead_sponsor_name":"Guangdong Association of Clinical Trials","has_results":false},{"nct_id":"NCT05537922","title":"I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":2200,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT07509333","title":"MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT06418204","title":"Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":false},{"nct_id":"NCT03232593","title":"A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)","phase":"","overall_status":"COMPLETED","enrollment_count":1758,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05337163","title":"A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China","phase":"","overall_status":"COMPLETED","enrollment_count":1564,"lead_sponsor_name":"Creative Biosciences (Guangzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT00324805","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1501,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04152499","title":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT07222566","title":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03939481","title":"Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1336,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT05176483","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT04738487","title":"Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1264,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04267848","title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1210,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05812027","title":"A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1150,"lead_sponsor_name":"TScan Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02453282","title":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1118,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06632327","title":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1100,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT00540514","title":"Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1052,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT04389632","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1006,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT06494241","title":"Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02542293","title":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":953,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04895709","title":"A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":949,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06131840","title":"A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":914,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT03170960","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":914,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT02595944","title":"Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":903,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05377788","title":"Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":900,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT07223424","title":"Patient Preference for Subcutaneous vs. Intravenous Immune Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":880,"lead_sponsor_name":"Diwakar Davar","has_results":false},{"nct_id":"NCT07469709","title":"A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks","phase":"","overall_status":"RECRUITING","enrollment_count":850,"lead_sponsor_name":"Fondazione del Piemonte per l'Oncologia","has_results":false},{"nct_id":"NCT05973487","title":"A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":840,"lead_sponsor_name":"TScan Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05633602","title":"Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":838,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT06073431","title":"LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT03819296","title":"Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05037825","title":"The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"VastBiome","has_results":false},{"nct_id":"NCT05379985","title":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":754,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT04401059","title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":744,"lead_sponsor_name":"Tian Xie","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT06481813","title":"Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":730,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT05208762","title":"A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":714,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT06758401","title":"This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":714,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03088540","title":"Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":712,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT02511106","title":"AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":682,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT07144280","title":"A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":680,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03003962","title":"Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":669,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04092283","title":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":660,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}